Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Probiotics in PSC and IBD
NCT00161148Phase 3Unknown
- Start
- Jan 2005
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Ecologic 641 in Primary Sclerosing Cholangitis (PSC) (2 arms). Primary endpoint: Serum liver biochemistry at 3 months. Status: unknown.
02
Drugs
Ecologic 641
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on NCT00161148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00161148.